Full-Time

Oncology Account Executive

Caris

Caris

1,001-5,000 employees

Provides AI-powered molecular insights for cancer

No salary listed

Oklahoma, USA

Remote

Regular travel is required, including possible evenings, weekends, or holidays.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Microsoft Office
Sales
CRM

Get referred to Caris

See people who can refer or advise you

Requirements
  • A bachelor's degree is required.
  • At least 3 years of relevant sales experience are required.
  • Strong understanding of oncology practices and molecular diagnostics is required.
  • Knowledge of billing and reimbursement environments is required.
  • The candidate must have proficiency with Microsoft Office and customer relationship management tools.
  • The candidate must be able to manage multiple priorities in a matrixed environment.
  • A valid driver's license and willingness to travel regularly are required.
  • The candidate must successfully complete pre-employment requirements, including applicable background, drug, credit, and reference checks.
Responsibilities
  • Drive new account acquisition and organic growth through strategic prospecting, value-based selling, and clinical education.
  • Position Caris as a preferred or sole-source provider of tumor profiling and molecular intelligence solutions.
  • Analyze territory opportunities and develop strategic sales plans to achieve growth objectives.
  • Meet or exceed assigned revenue, activity, and performance targets.
  • Build and maintain strong customer relationships through consistent in-person engagement.
  • Ensure a seamless customer experience across the full order lifecycle.
  • Maintain open communication with key account stakeholders and escalate issues when satisfaction is at risk.
  • Execute retention strategies and identify upselling and cross-selling opportunities.
  • Engage with oncology clinicians and allied teams across clinics, pathology laboratories, and hospital settings.
  • Support physicians with ordering and interpretation of the CMI platform, including access to protected health information when required.
  • Demonstrate and advise on technology solutions such as portals, electronic medical record integrations, and workflows.
  • Maintain strong knowledge of molecular profiling, biomarkers, and competitive offerings.
  • Provide consultative guidance on billing, reimbursement, and payer dynamics.
  • Serve as a resource on laboratory reimbursement and operational workflows.
  • Share market trends, customer feedback, and competitive insights with leadership.
  • Collaborate with Client Services, Regional Business Directors, Commercial Leadership, and cross-functional teams.
  • Maintain accurate customer relationship management documentation and complete required administrative tasks.
  • Maintain assigned company assets.
  • Support meetings, conferences, and trade shows as required.
  • Perform other duties as assigned.
Desired Qualifications
  • At least 5 years of sales experience with an oncology or molecular diagnostics focus.
  • Established oncology or pathology relationships.
  • Familiarity with hospital systems and pathology networks.

Caris Life Sciences provides molecular information to cancer patients, oncologists, researchers, and payors to guide personalized cancer care. Its core product uses molecular profiling and artificial intelligence to interpret a cancer’s molecular features at diagnosis, helping predict how the cancer may behave and which treatments are likely to work. The company differentiates itself by delivering a comprehensive, AI-assisted set of molecular insights across multiple stakeholders, translating complex genomic and other molecular data into actionable treatment guidance. Its goal is to improve cancer outcomes by enabling more precise, tailored therapy for each patient.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Irving, Texas

Founded

1996

Get referred to Caris

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $263.7 million, and guidance rose to $1.03 billion-$1.04 billion.
  • Q1 2026 gross margin reached 65%, with positive EBITDA and free cash flow.
  • PTEN testing, ChromoSeq, and MI Clarity broaden reimbursable products beyond core profiling.

What critics are saying

  • Whistleblower FCA claims in Northern Texas remain active, risking treble damages and exclusion.
  • Detect faces brutal MCED competition from Grail, Guardant, and Exact Sciences by 2027.
  • Founder David Dean Halbert owns 43.9%, limiting governance leverage for minority shareholders.

What makes Caris unique

  • Caris pairs whole-genome profiling with AI across 1 million cases and 50 billion markers.
  • MI Clarity delivers breast recurrence risk from routine pathology slides within three business days.
  • Caris Detect uses ultra-deep WGS, WTS, and Everlywell distribution for MCED commercialization.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Company Match

Employee Assistance Program

Pet Insurance

Legal Assistance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
PR Newswire
Aug 6th, 2026
AI model predicts late breast cancer recurrence risk from standard pathology images

Caris Life Sciences has published research demonstrating a multimodal AI approach to predict late distant recurrence risk in hormone receptor-positive early breast cancer. The study appeared in Cancer Research Communications. The research, conducted with ECOG-ACRIN and NRG Oncology, integrated digitised pathology images with clinical data to generate risk predictions. The model was developed using specimens from 2,271 patients and validated in an independent cohort of 4,300 patients from the TAILORx study. In validation, the model identified a 10-year absolute distant recurrence risk difference of nearly 8% between high- and low-risk groups. It independently predicted late recurrence risk even after accounting for established clinical factors and the Oncotype DX Recurrence Score. The AI-based approach could offer a more accessible alternative to existing genomic assays by leveraging routinely available pathology slides, potentially helping oncologists identify patients at elevated risk and inform extended endocrine therapy decisions.

PR Newswire
Jul 14th, 2026
Caris Life Sciences launches PTEN IHC testing for metastatic prostate cancer precision treatment

Caris Life Sciences announced it will offer in-house PTEN immunohistochemistry testing following recent FDA approval of a biomarker-guided therapy for metastatic prostate cancer. The testing helps identify patients with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive prostate cancer who are eligible for newly approved biomarker-guided therapy. Prostate cancer affects more than 300,000 new cases annually in the US. One in four patients with this type of metastatic prostate cancer have PTEN-deficient tumours, which are associated with faster progression and worse outcomes. The FDA approved capivasertib, combined with abiraterone and prednisone, for adults with PTEN-deficient tumours. Caris' testing will be performed in its CAP-accredited, CLIA-certified laboratories to deliver results efficiently for clinical decision-making. The company's molecular profiling portfolio includes MI Cancer Seek, Caris Assure, and Caris Detect, amongst other diagnostic solutions.

Dallas Next
Jul 6th, 2026
Caris Life Sciences begins commercial launch of multi-cancer early detection blood test.

Caris Life Sciences begins commercial launch of multi-cancer early detection blood test. "We are giving physicians and patients a powerful new tool to help identify cancer earlier and support more informed clinical decisions," CEO David Dean Halbert says of Caris Detect. Caris Life Sciences has begun the commercial launch of a blood test designed to detect early signals for multiple types of cancer. [Photo: Caris Life Sciences] Irving-based Caris Life Sciences began the commercial launch of Caris Detect, a blood test designed to detect signals for multiple types of cancer earlier than previously possible. Early detection is key to improving cancer outcomes for patients. Overall five-year cancer survival has climbed to 70%, according to the American Cancer Society's Cancer Facts & Figures 2026 report. Yet individual results vary widely depending on timing. Patients whose cancer is localized have a 92% five-year survival rate. That survival rate drops to 69% for those whose cancer is regional and to 35% for those whose cancer has spread to distant parts of the body. Caris Detect pairs an analysis of the entire genome with advanced AI trained on 50 billion molecular markers from more than 1 million patient cases. "Early detection remains one of the most urgent and consequential challenges in oncology," David Dean Halbert, founder, chairman and CEO, said in a statement. "Caris Detect represents a major step forward in our mission to transform cancer care through the most advanced molecular science available. By combining unmatched biological depth with sophisticated AI, we are giving physicians and patients a powerful new tool to help identify cancer earlier and support more informed clinical decisions." How patients can use the new test Caris Detect is available through physicians. Patients go to an approved lab for their blood draw, and the lab then sends the Caris Detect kit to Caris for processing. Caris then sends the results to the patient and health-care provider. The test returns one of three possible results. If it doesn't detect a cancer signal, Caris recommends patients continue with their routine screening schedule. An atypical signal indicates a minor abnormality. For these, Caris provides complimentary repeat testing approximately three months after the initial result and recommends that providers establish a monitoring plan. If the test detects a cancer signal, Caris provides additional support including referrals and recommendations for next steps. A North Texas life sciences leader Since its founding in 2008, Caris Life Sciences has made its mark as a pioneer in bringing a combination of genetic sequencing, AI, machine learning and other advancements to the field of precision medicine. In addition to its Irving headquarters, Caris has established offices in Phoenix, New York, Cambridge, Massachusetts, Tokyo and Basel, Switzerland. The company raised nearly $2 billion before going public on the Nasdaq in June 2025, with investors including Sixth Street, Braidwell LP, Perceptive Advisors, Woodline, Ghisallo, Millennium Management and First Light Asset Management. In June, Caris added a dual listing of its common stock on NYSE Texas. "Establishing a dual listing on NYSE Texas reflects both our continued growth as a public company and our deep roots in Texas, including our headquarters and over 450 Caris employees in the state," Halbert said. "This milestone underscores our commitment to innovation, our heritage in Texas and our mission to improve the lives of patients through precision medicine." When it announced its first-quarter earnings in May, Caris Life Sciences reaffirmed its guidance for full-year 2026 revenue to be in the range of $1.0 billion to $1.02 billion. That would be 23% to 26% higher than in 2025.

PR Newswire
Jul 1st, 2026
Caris Life Sciences launches Caris Detect, world's most sensitive multi-cancer early detection blood test

Caris Life Sciences has launched Caris Detect, a multi-cancer early detection blood test that combines ultra-deep whole genome and whole transcriptome sequencing with artificial intelligence. The company claims it is the world's most sensitive and comprehensive cancer detection technology. Unlike existing approaches that examine limited genomic changes, Caris Detect analyses the full spectrum of genomic and molecular signals, including DNA, RNA and other biological patterns. The test is powered by Caris' molecular profiling database containing over one million cases and 50 billion molecular markers. The launch follows the Caris Detect ACHIEVE 1 study, which demonstrated strong performance in detecting cancer signals across multiple cancer types. The Irving, Texas-based precision medicine company aims to establish the test as a new standard of care for early cancer detection.

AInvest Fintech Inc.
Jun 30th, 2026
Caris Life Sciences, Inc. (CAI) stock poised for growth with ai-driven precision medicine expansion.

Caris Life Sciences, Inc. (CAI) stock poised for growth with ai-driven precision medicine expansion. Tuesday, Jun 30, 2026 9:25 am ET 1min read Caris Life Sciences, Inc. (CAI) is a TechBio and precision medicine company expanding with AI-driven precision medicine. The company has been added to the list of 10 Most Promising Cancer Stocks According to Wall Street Analysts. CAI announced a dual listing on NYSE Texas, effective June 17, 2026, expanding visibility among investors in Texas and across the U.S. market. The company's focus on advancing AI-driven precision medicine and improving patient outcomes through innovative healthcare solutions supports its growth. Caris Life Sciences, Inc. (CAI) has been recognized as one of the 10 Most Promising Cancer Stocks by Wall Street analysts[1]. The company, which operates at the intersection of technology and biotechnology (TechBio), is advancing AI-driven precision medicine to improve patient outcomes in oncology. CAI's strategic expansion includes dual listing on NYSE Texas, effective June 17, 2026. This move is expected to increase the company's visibility among investors in Texas and across the U.S. market. The company's focus on leveraging artificial intelligence to enhance diagnostic and therapeutic solutions supports its long-term growth trajectory. As the healthcare sector continues to evolve, CAI's commitment to innovation in precision medicine positions it as a key player in the oncology space. Investors are advised to monitor the company's progress in implementing its strategic initiatives and the potential impact of its expanded market presence on investor engagement and financial performance. Ask Aime: What impact will CAI's dual listing on NYSE Texas have on its stock performance? Aime insights. Could you find stocks channeling up? What's the performance trend of major Indian companies listed on US stock exchanges? Which AI stocks have a consensus buy rating?